Cellular therapy of cancer with natural killer cells—where do we stand?
- 31 October 2013
- journal article
- review article
- Published by Elsevier BV in Cytotherapy
- Vol. 15 (10), 1185-1194
- https://doi.org/10.1016/j.jcyt.2013.03.011
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid LeukemiaBlood, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- MSCs in Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorBlood, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Mesenchymal stem cells in health and diseaseNature Reviews Immunology, 2008
- Cancer despite immunosurveillance: immunoselection and immunosubversionNature Reviews Immunology, 2006
- Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaBlood, 2000
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998